Cita APA

Jain, V., Giménez Arnau, A. M., Hayama, K., Reich, A., Carr, W., Tillinghast, J., . . . Haemmerle, S. (2024). Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.

Citación estilo Chicago

Jain, Vipul, et al. Remibrutinib Demonstrates Favorable Safety Profile and Sustained Efficacy in Chronic Spontaneous Urticaria Over 52 Weeks. 2024.

Cita MLA

Jain, Vipul, et al. Remibrutinib Demonstrates Favorable Safety Profile and Sustained Efficacy in Chronic Spontaneous Urticaria Over 52 Weeks. 2024.

Precaución: Estas citas no son 100% exactas.